US Bancorp
ORKA

US Bancorp’s Oruka Therapeutics ORKA Stock Holding History

US Bancorp’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Sell
4,194
-671
-14% -$44.7K ﹤0.01% 1721
2026
Q1 		$239K Buy
4,865
+1,940
+66% +$67.4K ﹤0.01% 1924
2025
Q4 		$88.7K Buy
2,925
+2,747
+1,543% +$76.5K ﹤0.01% 2441
2025
Q3 		$3.42K Buy
+178
New +$2.64K ﹤0.01% 3642

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

US Bancorp's ORKA Position: Q2 2026 in Review

US Bancorp reduced its Oruka Therapeutics (ORKA) stake by 14% in Q2 2026, selling an estimated $44.7K and leaving 4,194 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

US Bancorp first reported a position in ORKA in Q3 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • US Bancorp held 4,194 shares of Oruka Therapeutics worth $399K as of Q2 2026.
  • US Bancorp sold 671 Oruka Therapeutics shares in Q2 2026, an estimated $44.7K.
  • Oruka Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1721 holding.
  • US Bancorp first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.